Stock Ticker

  • Loading stock data...

Capricor Therapeutics Inc (NASDAQ:CAPR) Progresses With Its Lead Investigational Product

Capricor Therapeutics Inc (NASDAQ:CAPR) in a poster presentation released report which support the peripheral intravenous administration method the firm intends to use in HOPE-2, its intended next clinical study of its lead investigational offering, CAP-1002, for the cure of Duchenne muscular dystrophy. The details CAP-1002 comprises of allogeneic cardiosphere-derived cells, whose mechanism of action is […]

Sign Up To Get Our Latest Stocks Alerts